Assessing the effects of naltrexone‐bupropion on hepatic steatosis and fibrosis in patients with <scp>T2DM</scp> and overweight or obesity: Insights from a placebo‐controlled trial
Weight loss was the key driver of hepatic improvements in patients with T2DM and overweight or obesity. Treatment with NB resulted in significantly greater weight reduction and significantly greater improvements in HSI and MAF-5 compared with placebo, suggesting an added benefit for liver health.
Authors
- Simone P. Rauh (ORCID: https://orcid.org/0000-0003-3627-6925)
- Aart‐Jan van der Lelij
- Vivian de Jong (ORCID: https://orcid.org/0000-0002-4692-479X)
- Martien van Wenum
- Carmen A. W. Dietvorst (ORCID: https://orcid.org/0009-0005-3936-0411)
- Weiwei Xu (ORCID: https://orcid.org/0000-0003-0976-2290)
- Willem Pieter Brouwer (ORCID: https://orcid.org/0000-0001-8713-1481)
- Marco Alings
- L Konings
- Manuel Castro Cabezas (ORCID: https://orcid.org/0009-0009-5164-2082)
- Alina Saidi (ORCID: https://orcid.org/0009-0003-9732-430X)
Institutions
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- Sint Franciscus Gasthuis (NL)
- Amphia Ziekenhuis (NL)
- Yulius (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1111/dom.70071
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Diabetes Association